Anticyclic citrullinated protein antibodies are implicated in the development of cardiovascular disease in rheumatoid arthritis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 12, 2014, Pages 2706-2716

  Barbarroja, Nuria ^a   Pérez Sanchez, Carlos ^a   Ruiz Limon, Patricia ^a   Castro Villegas, Carmen ^a   Aguirre, Maria Angeles ^a   Carretero, Rosario ^a   Segui, Pedro ^b   Jimenez Gomez, Yolanda ^a   Sanna, Manuela ^a,c   Rodriguez Ariza, Antonio ^a   Collantes Estevez, Eduardo ^a   Escudero, Alejandro ^a   López Pedrera, Chary ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b Radiology Service   (Spain)

^c UNIVERSITY OF SASSARI   (Italy)

Author keywords

Cardiovascular disease; Inflammation; Leukocytes; Rheumatoid arthritis

Indexed keywords

ANTICYCLIC CITRULLINATED PROTEIN; CD11B ANTIGEN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; L SELECTIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PROCOAGULANT; PROTEIN ANTIBODY; SELECTINE; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; AUTACOID; AUTOANTIBODY; BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; TRANSCRIPTOME;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL POPULATION; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; IN VITRO STUDY; INFLAMMATION; LEUKOCYTE; LEUKOCYTE ACTIVATION; LYMPHOCYTE; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPHIL; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SURVIVAL RATE; THROMBOSIS; AGED; BLOOD; CARDIOVASCULAR DISEASES; CAROTID ARTERY DISEASES; CASE CONTROL STUDY; COMPLICATION; GENETICS; IMMUNOLOGY; MIDDLE AGED;

AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LEUKOCYTES; MALE; MIDDLE AGED; OXIDATIVE STRESS; PEPTIDES, CYCLIC; TRANSCRIPTOME;

EID: 84918808898     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.304475     Document Type: Article

References (49)

1. del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44:2737-2745.
2. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, Gabriel SE. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005;52:402-411.
3. Gonzalez-Juanatey C, Llorca J, Testa A, Revuelta J, Garcia-Porrua C, Gonzalez-Gay M.A. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore). 2003;82:407-413.
4. Ku IA, Imboden JB, Hsue PY, Ganz P. Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis. Circ J. 2009;73:977-985.
5. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
6. Hitchon C.A., El-Gabalawy HS. Oxidation in rheumatoid arthritis. Arthritis Res Ther. 2004;6:265-278.
7. Kundu S, Ghosh P, Datta S, Ghosh A, Chattopadhyay S, Chatterjee M. Oxidative stress as a potential biomarker for determining disease activity in patients with rheumatoid arthritis. Free Radic Res. 2012;46:1482-1489.
8. Ostrakhovitch EA, Afanas'ev IB. Oxidative stress in rheumatoid arthritis leukocytes: suppression by rutin and other antioxidants and chelators. Biochem Pharmacol. 2001;62:743-746.
9. Lioté F, Boval-Boizard B, Weill D, Kuntz D, Wautier JL. Blood monocyte activation in rheumatoid arthritis: increased monocyte adhesiveness, integrin expression, and cytokine release. Clin Exp Immunol. 1996;106:13-19.
10. Kinne RW, Stuhlmuller B, Burmester GR. Cells of the synovium in rheumatoid arthritis. Macrophages [Review]. Arthritis Res Ther. 2007; 9: 224.
11. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007;7:292-304.
12. Chen J, Li J, Gao H, Wang C, Luo J, Lv Z, Li X. Comprehensive evaluation of different T-helper cell subsets differentiation and function in rheumatoid arthritis. J Biomed Biotechnol. 2012;2012:535361.
13. Lubberts E. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine. 2008;41:84-91.
14. Németh T, Mócsai A. The role of neutrophils in autoimmune diseases. Immunol Lett. 2012;143:9-19.
15. Van Venrooij WJ, Hazes JM, Visser H. Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med. 2002;60:383-388.
16. Kerola AM, Kerola T, Kauppi MJ, Kautiainen H, Virta LJ, Puolakka K, Nieminen TV. Cardiovascular comorbidities antedating the diagnosis of rheumatoid arthritis. Ann Rheum Dis. 2013;72:1826-1829.
17. Nielen MM, Van Schaardenburg D, Reesink HW, Van de Stadt RJ, Van Der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Van Der Horst-Bruinsma IE, Dijkmans BA. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50:380-386.
18. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-2581.
19. Fransen J, Stucki G, Van Riel LCM. Rheumatoid Arthritis Measures. Arthritis Rheum (Arthritis Care & Research). 2003;49:S214-S224
20. Engelmann R, Brandt J, Eggert M, Karberg K, Krause A, Neeck G, Mueller-Hilke B. IgG1 and IgG4 are the predominant subclasses among auto-antibodies against two citrullinated antigens in R.A. Rheumatology (Oxford). 2008;47:1489-1492.
21. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, Saigo K, Morinobu A, Koshiba M, Kuntz KM, Kamae I, Kumagai S. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146:797-808.
22. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anticyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2006;65:845-851.
23. Bos WH, Wolbink GJ, Boers M, Tijhuis GJ, de Vries N, Van Der Horst-Bruinsma IE, Tak PP, Van de Stadt RJ, Van Der Laken CJ, Dijkmans BA, Van Schaardenburg D. Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis. 2010;69:490-494.
24. Lundberg K, Nijenhuis S, Vossenaar ER, Palmblad K, Van Venrooij WJ, Klareskog L, Zendman AJ, Harris HE. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther. 2005;7:R458-R467.
25. Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson WH, Holers VM. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest. 2006;116:961-973.
26. Arnab B, Biswadip G, Arindam P, Shyamash M, Anirban G, Rajan P. Anti-CCP antibody in patients with established rheumatoid arthritis: does it predict adverse cardiovascular profile? J Cardiovasc Dis Res. 2013;4:102-106.
27. Kalpakcioglu B, Senel K. The interrelation of glutathione reductase, catalase, glutathione peroxidase, superoxide dismutase, and glucose-6-phosphate in the pathogenesis of rheumatoid arthritis. Clin Rheumatol. 2008;27:141-145.
28. Hassan SZ, Gheita TA, Kenawy SA, Fahim AT, El-Sorougy IM, Abdou MS. Oxidative stress in systemic lupus erythematosus and rheumatoid arthritis patients: relationship to disease manifestations and activity. Int J Rheum Dis. 2011;14:325-331.
29. Ostrakhovitch EA, Afanas'ev IB. Oxidative stress in rheumatoid arthritis leukocytes: suppression by rutin and other antioxidants and chelators. Biochem Pharmacol. 2001;62:743-746.
30. Moodley D, Mody G, Patel N, Chuturgoon AA. Mitochondrial depolarisation and oxidative stress in rheumatoid arthritis patients. Clin Biochem. 2008;41:1396-1401.
31. Pedersen-Lane JH, Zurier RB, Lawrence D.A. Analysis of the thiol status of peripheral blood leukocytes in rheumatoid arthritis patients. J Leukoc Biol. 2007;81:934-941.
32. Mikuls TR, Gould KA, Bynoté KK, et al. Anticitrullinated protein antibody (ACP.A.) in rheumatoid arthritis: influence of an interaction between HL.A.-DRB1 shared epitope and a deletion polymorphism in glutathione S-transferase in a cross-sectional study. Arthritis Res Ther. 2010;12:R213.
33. Ediz L, Hiz O, Ozkol H, Gulcu E, Toprak M, Ceylan MF. Relationship between anti-CCP antibodies and oxidant and anti-oxidant activity in patients with rheumatoid arthritis. Int J Med Sci. 2011;8:139-147.
34. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7:429-442.
35. Hitchon C.A., Alex P, Erdile LB, Frank MB, Dozmorov I, Tang Y, Wong K, Centola M, El-Gabalawy HS. A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis. J Rheumatol. 2004;31:2336-2346.
36. Gómez-Puerta JA, Celis R, Hernández MV, Ruiz-Esquide V, Ramírez J, Haro I, Cañete JD, Sanmartí R. Differences in synovial fluid cytokine levels but not in synovial tissue cell infiltrate between anti-citrullinated peptide/protein antibody-positive and-negative rheumatoid arthritis patients. Arthritis Res Ther. 2013;15:R182.
37. Van Hamburg JP, Corneth OB, Paulissen SM, Davelaar N, Asmawidjaja PS, Mus AM, Lubberts E. IL-17/Th17 mediated synovial inflammation is IL-22 independent. Ann Rheum Dis. 2013;72:1700-1707
38. Marder W, Khalatbari S, Myles JD, Hench R, Yalavarthi S, Lustig S, Brook R, Kaplan MJ. Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis. Ann Rheum Dis. 2011;70:1550-1555.
39. Van Es T, Van Puijvelde GHM, Ramos OH Segers FM, Joosten L.A., Van den Berg WB, Michon IM, de Vos P, Van Berkel TJ, Kuiper J. Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice. Biochem Biophys Res Commun 2009;388:261-265
40. Evans HG, Gullick NJ, Kelly S, Pitzalis C, Lord GM, Kirkham BW, Taams LS. In vivo activated monocytes from the site of inflammation in humans specifically promote Th17 responses. Proc Natl Acad Sci U S A. 2009;106:6232-6237.
41. Noack M, Thiam N, Miossec P. Interaction between fibroblast and T lymphocytes is needed for IL-17 secretion and Th17 differentiation requires T cell activation. Ann Rheum Dis. 2014;73(Suppl 1):A29.
42. Li J, Hsu HC, Mountz JD. Managing macrophages in rheumatoid arthritis by reform or removal. Curr Rheumatol Rep. 2012;14:445-454.
43. Peng SL. Fas (CD95)-related apoptosis and rheumatoid arthritis. Rheumatology. 2006;45:26-30
44. Hatano Y, Kasama T, Iwabuchi H, Hanaoka R, Takeuchi HT, Jing L, Mori Y, Kobayashi K, Negishi M, Ide H, Adachi M. Macrophage inflammatory protein 1 alpha expression by synovial fluid neutrophils in rheumatoid arthritis. Ann Rheum Dis. 1999;58:297-302.
45. Koch AE, Kunkel SL, Harlow L.A., Mazarakis DD, Haines GK, Burdick MD, Pope RM, Strieter RM. Macrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis. J Clin Invest. 1994;93:921-928.
46. Mantovani A, Cassatella M.A., Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol. 2011;11:519-531.
47. Gerli R, Bartoloni Bocci E, Sherer Y, Vaudo G, Moscatelli S, Shoenfeld Y. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:724-725.
48. El-Barbary AM, Kassem EM, El-Sergany M.A., Essa SA, Eltomey M.A. Association of anti-modified citrullinated vimentin with subclinical atherosclerosis in early rheumatoid arthritis compared with anti-cyclic citrullinated peptide. J Rheumatol. 2011;38:828-834.
49. Sokolove J, Brennan MJ, Sharpe O, Lahey LJ, Kao AH, Krishnan E, Edmundowicz D, Lepus CM, Wasko MC, Robinson WH. Brief report: citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis. Arthritis Rheum. 2013;65:1719-1724.